Dysfunction of the dopaminergic pathway has been postulated to underlie the symptomatology of Tourette's syndrome. Presynaptic functional integrity of dopaminergic terminals was assessed with '8F-dopa PET in 10 patients with Tourette's syndrome, three of whom were drug free and seven of whom were on neuroleptic treatment. Dopamine D, receptor site density was measured with
"IC-raclopride PET in a firther group of five drug free patients with Tourette's syndrome. Mean caudate and putamen '8F-dopa influx constants were similar in patients with Tourette's syndrome and controls, and there was no difference in striatal '8F-dopa uptake between the treated and untreated Tourette's syndrome groups. Mean caudate and putamen "IC-raclopride binding potentials in patients with Tourette's syndrome were also similar to control values. The findings suggest that striatal metabolism of exogenous levodopa and the density of striatal D, receptors are both normal in patients with Tourette's syndrome and that Tourette's syndrome does not arise from a primary dysfunction of dopaminergic terminals.
(7 Neurol Neurosurg Psychiatry 1994;57:688-692) lowing clinical observations: (1) tics usually respond to dopamine receptor antagonists (neuroleptics) and dopamine depleting agents (reserpine, tetrabenazine). (2) Exacerbations of tics have been reported in patients with Tourette's syndrome exposed to dopamine reuptake inhibitors such as cocaine,56 and to amphetamines.7 (3) Neuroleptic withdrawal can lead to tics. 8 There is also pathological evidence supporting dysfunction of dopaminergic transmission in Tourette's syndrome. Baseline concentrations of dopamine metabolites have been reported to be reduced in the CSF of patients with Tourette's syndrome.9 10 Postmortem studies with [3H]mazindol" found increased dopamine re-uptake site density in striatum from patients with Tourette's syndrome.
To help clarify whether dopaminergic dysfunction underlies Tourette's syndrome, we have assessed the functional integrity of the presynaptic and postsynaptic dopaminergic system with the PET tracers '8F-dopa and "IC-raclopride. The Patients studied with '"C-raclopride PET Five men with Tourette's syndrome were studied with "IC-raclopride; three had not received drugs, two ceased neuroleptic treatment at least three months before PET, one of them had not received neuroleptics for at least three years before this study. Their mean age when studied was 33 (range 18-46) years, and disease onset occurred at a mean age of 8 (range 5-12) years. One of these patients was also studied with 18F-dopa PET. Table 2 gives the patients' details.
The findings were compared with those of nine control subjects, mean age 50 (range MBq potentials in Tourette's syndrome were similar to control values. Figure 2 shows individual caudate and putamen binding potentials for Tourette's syndrome and control subjects. All except one lay within two SDs of the normal means. When the patients with Tourette's syndrome were compared with a smaller subgroup of five age matched normal controls, mean binding potentials of both groups remained similar (mean normal caudate: 2-36 (0l19) and putamen: 2-45 (0 07)).
Discussion
Our nine patients with Tourette's syndrome and one patient with multiple tic disease studied with '8F-dopa PET all had normal uptake and storage of this tracer in their nigrostriatal dopaminergic terminals. A further group of five patients with Tourette's syndrome studied with '"C-raclopride exhibited normal postsynaptic striatal D2 receptor binding potentials. As seven of the 10 patients scanned with '8F-dopa were receiving chronic neuroleptic treatment at the time of PET it is necessary to consider the effects of these drugs on the activity of aromatic amino acid decarboxylase, the enzyme in the dopaminergic terminals responsible for decarboxylating exogenous 18F-dopa. The effects of acute neuroleptic treatment on the dopaminergic presynaptic projections are well established; however, the effects of chronic treatment are still uncertain. Studies on rats have shown increased release of striatal dopamine, and increased aromatic amino acid decarboxylase activity, after acute challenges with dopamine DI and D, antagonists. '7 18 Chronic haloperidol treatment decreased basal dopamine release,'9 although we have been unable to find data about its effect on aromatic amino acid decarboxylase activity. Our own preliminary experiments suggest that such activity may become mildly raised in the rat striatum (Opacka-Juffry, personal communication). This could lead to a slight increase in striatal '8F-dopa uptake, although none was evident in our Tourette's syndrome group.
Decreased concentrations of the dopamine metabolite homovanillic acid and the serotonin metabolite 5-hydroxyindoleacetic acid have been reported in the CSF of patients with Tourette's syndrome.9 10 Postmortem studies with [3H]mazindol, have suggested increased dopaminergic reuptake site density (37% in caudate and 50% in putamen) in patients with Tourette's syndrome. Concentrations of dopamine and its metabolites in the striatum were, however, normal." The striatal concentration of adenosine 3',5'-monophosphate (cyclic AMP) has also been reported to be reduced in four patients with Tourette's syndrome. 20 In the light of these findings, it has been postulated that the primary defect in Tourette's syndrome could be abnormal dopamine turnover within the striatum, or abnormal second messenger production." 20 In our '8F-dopa PET study all patients with Tourette's syndrome had caudate and putamen influx constants within two SDs of the normal mean. Consequently, our PET findings do not support the presence of a primary dysfunction of dopa metabolism in the presynaptic dopaminergic terminals.
Rituals and obsessive behaviour were a clinical feature in nine of our 10 patients studied with '8F-dopa. Our Metabolic PET studies in patients with Tourette's syndrome under resting condition have shown hypermetabolism in selective areas of the brain. A preliminary '8F-2-fluoro-2-deoxyglucose (18FDG) PET study in drug free patients with Tourette's syndrome found a 16% increase in glucose utilisation in the basal ganglia of patients with Tourette's syndrome compared with controls and relative hypermetabolism in frontal and temporal areas bilaterally.24 Later, the same group reported regional hypermetabolism in superior frontal and sensorimotor cortices and suggested that the normal relation between the function of motor cortex and other brain regions was disturbed.25 A confounding problem, however, is that these patients may have had tics during the 18FDG PET. It remains unclear, therefore, how much of the increased activity represented tic generation, and how much simply reflected increased motor activity. Sawle et a126 recently reported a PET study of regional cerebral oxygen metabolism before and after cingulotomy in a patient with Tourette's syndrome. Interestingly, preoperatively there was caudate and thalamus hypermetabolism, but after cingulotomy the metabolic rate decreased considerably in the caudate, in association with improvement of both tics and obsessive-compulsive syndrome.
In conclusion, using '8F-dopa and "1C-raclopride PET, we have been unable to find any abnormality of dopamine metabolism and storage in the nigrostriatal dopaminergic terminals, or in the density of striatal postsynaptic D2 receptors in patients with Tourette's syndrome. Our findings, however, do not exclude a dysfunction of endogenous dopamine production, or altered proportions of D2 receptors in high and low agonist affinity conformations7 in this condition.
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